Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell)

BIOLOGICAL2 trials

Sponsors

MAXVAX Biotechnology Limited Liability Company

Conditions

Respiratory Syncytial Virus (RSV)

Phase 3

Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)

RecruitingNCT07272434

MAXVAX Biotechnology Limited Liability CompanyRespiratory Syncytial Virus (RSV)

Start: 2025-10-22End: 2028-12-31Target: 25000Updated: 2025-12-09

Unknown Phase

A Study to Evaluate the Immune Response Features Following Vaccination With a Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)

Not yet recruitingNCT07618325

MAXVAX Biotechnology Limited Liability CompanyRespiratory Syncytial Virus (RSV)

Start: 2026-06-02End: 2028-08-31Target: 60Updated: 2026-06-01